S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.68 (-1.02%)
MSFT   214.59 (-0.10%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,176.00 (-0.28%)
TSLA   426.21 (+0.84%)
NVDA   532.00 (-1.66%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.47 (+0.34%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.99 (+4.62%)
NFLX   485.23 (-0.78%)
BA   169.13 (+3.22%)
NIO   27.41 (-1.62%)
BAC   24.88 (+3.45%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.68 (-1.02%)
MSFT   214.59 (-0.10%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,176.00 (-0.28%)
TSLA   426.21 (+0.84%)
NVDA   532.00 (-1.66%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.47 (+0.34%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.99 (+4.62%)
NFLX   485.23 (-0.78%)
BA   169.13 (+3.22%)
NIO   27.41 (-1.62%)
BAC   24.88 (+3.45%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.68 (-1.02%)
MSFT   214.59 (-0.10%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,176.00 (-0.28%)
TSLA   426.21 (+0.84%)
NVDA   532.00 (-1.66%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.47 (+0.34%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.99 (+4.62%)
NFLX   485.23 (-0.78%)
BA   169.13 (+3.22%)
NIO   27.41 (-1.62%)
BAC   24.88 (+3.45%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.21 (+0.01%)
AAPL   115.68 (-1.02%)
MSFT   214.59 (-0.10%)
FB   278.42 (-0.11%)
GOOGL   1,607.28 (+1.34%)
AMZN   3,176.00 (-0.28%)
TSLA   426.21 (+0.84%)
NVDA   532.00 (-1.66%)
BABA   306.36 (-0.52%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   53.88 (+1.07%)
AMD   79.47 (+0.34%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   62.99 (+4.62%)
NFLX   485.23 (-0.78%)
BA   169.13 (+3.22%)
NIO   27.41 (-1.62%)
BAC   24.88 (+3.45%)
Log in
NASDAQ:IFRX

Inflarx Stock Forecast, Price & News

$4.68
-0.06 (-1.27 %)
(As of 10/22/2020 03:59 PM ET)
Add
Compare
Today's Range
$4.68
Now: $4.68
$4.79
50-Day Range
$3.70
MA: $4.46
$5.14
52-Week Range
$2.25
Now: $4.68
$9.70
Volume2,443 shs
Average Volume858,723 shs
Market Capitalization$122.94 million
P/E RatioN/A
Dividend YieldN/A
Beta0.46
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Read More
Inflarx logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IFRX
CUSIPN/A
CIKN/A
Phone49-36-4150-8180
Employees36

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share

Profitability

Net Income$-59,650,000.00

Miscellaneous

Market Cap$122.94 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$4.68
-0.06 (-1.27 %)
(As of 10/22/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inflarx (NASDAQ:IFRX) Frequently Asked Questions

How has Inflarx's stock price been impacted by Coronavirus?

Inflarx's stock was trading at $3.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IFRX shares have increased by 44.9% and is now trading at $4.68.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Inflarx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Inflarx
.

When is Inflarx's next earnings date?

Inflarx is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Inflarx
.

How were Inflarx's earnings last quarter?

Inflarx NV (NASDAQ:IFRX) announced its quarterly earnings data on Thursday, July, 30th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.
View Inflarx's earnings history
.

What price target have analysts set for IFRX?

6 brokers have issued 1-year price targets for Inflarx's stock. Their forecasts range from $7.00 to $19.00. On average, they expect Inflarx's share price to reach $10.50 in the next year. This suggests a possible upside of 124.4% from the stock's current price.
View analysts' price targets for Inflarx
.

Are investors shorting Inflarx?

Inflarx saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 465,300 shares, an increase of 20.1% from the September 15th total of 387,500 shares. Based on an average daily trading volume, of 631,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 2.4% of the company's stock are short sold.
View Inflarx's Short Interest
.

Who are some of Inflarx's key competitors?

What other stocks do shareholders of Inflarx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inflarx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Opko Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

Who are Inflarx's key executives?

Inflarx's management team includes the following people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 47)
  • Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 49)
  • Mr. Arnd Christ, Chief Financial Officer (Age 53)
  • Mr. Jason M. Marks J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 43)
  • Mr. Jordan Silverstein, Head of Corp. Devel. & Strategy

When did Inflarx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is Inflarx's stock symbol?

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

Who are Inflarx's major shareholders?

Inflarx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FNY Investment Advisers LLC (1.33%).

Which major investors are buying Inflarx stock?

IFRX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC.

How do I buy shares of Inflarx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inflarx's stock price today?

One share of IFRX stock can currently be purchased for approximately $4.68.

How big of a company is Inflarx?

Inflarx has a market capitalization of $122.94 million. The company earns $-59,650,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Inflarx employs 36 workers across the globe.

What is Inflarx's official website?

The official website for Inflarx is www.inflarx.de.

How can I contact Inflarx?

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.